Epigenetic reprogramming of cancer stem cells to tumor cells using ultrasmall gold nanoparticle
Source abstract
Abstract
Epigenetic reprogramming of cancer stem-like cells (CSC) is crucial to the clinical implementation of efficient tumor management. Groups of methylation on genomic DNA are a relatively stable epigenetic component. They are key drivers in the formation and maintenance of CSCs. Hence, reprogramming the DNA methylation epigenetics can provide new insights into cancer therapeutic approaches. Nanoprobes can influence CSC epigenetics; however, existing nanoprobes induce epigenetic alterations in an unregulated manner, which might result in undesirable mutation accumulation, which can hinder the reprogramming process. Here we report an epigenetic reprogramming approach with an ultrasmall Au NP, which can demethylate the genomic DNA, thereby causing the reprogramming of CSCs to cancer cells. In vitro bench top verification on preclinical models of non-metastatic and metastatic lung CSC showed a significant decrease in genetic, phenotypic stemness, and cell cycle quiescence, validated with biological assays. Furthermore, the ultrasmall Au NP was shown to interact with the epigenetic environment of CSCs through gold-DNA affinity spectral analysis. The pilot clinical validation study established the potential of our approach for clinical implementation. To the best of our knowledge, this is the first study to demonstrate a CSC epigenetic reprogramming using nanoparticles. In summary, this paper demonstrated that the nanoprobe could actively modify epigenetics and, as a result, can be employed to mitigate CSC stemness. Our findings might pave the path for more effective anti-cancer treatments and precision nanomedicine in the future.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · Graphene and Nanomaterials Applications · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (57)
Show source-provided references
1. Natural products in the reprogramming of cancer epigenetics10.1016/j.taap.2021.115467 ↗
2. Remodeling the Epigenetic Landscape of Cancer—Application Potential of Flavonoids in the Prevention and Treatment of Cancer
3. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials10.1038/s41392-019-0095-0 ↗
4. Toh · Epigenetics in cancer stem cells · 2017 · 16 · 29
5. Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance10.1186/s13148-021-01107-4 ↗
6. Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity10.1016/j.trecan.2017.04.004 ↗
7. Targeting Cancer Stem Cells: A Strategy for Effective Eradication of Cancer10.3390/cancers11050732 ↗
8. The Role of Cancer Stem Cells in Radiation Resistance10.3389/fonc.2020.00164 ↗
9. Epigenetic reprogramming of cell identity: lessons from development for regenerative medicine10.1186/s13148-021-01131-4 ↗
10. DNA methylation: An epigenetic mark of cellular memory10.1038/emm.2017.10 ↗
11. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives10.1038/s41392-021-00572-w ↗
12. Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy10.3389/fphar.2021.702360 ↗
13. Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges10.3389/fcell.2021.694363 ↗
14. DNA demethylation and invasive cancer: implications for therapeutics10.1111/bph.12885 ↗
15. Site-Specific DNA Demethylation as a Potential Target for Cancer Epigenetic Therapy10.1177/2516865720964808 ↗
16. J. Zhang, C. Yang, C. Wu, W. Cui, L. Wang, DNA Methyltransferases in Cancer: Biology, Paradox, Aberrations, and Targeted Therapy, Cancers. 12 (2020) 2123. https://doi.org/10.3390/cancers12082123.10.3390/cancers12082123 ↗
17. Epigenetic Effects of Nanomaterials and Nanoparticles10.1186/s12951-020-00740-0 ↗
18. Epigenetic aspects of engineered nanomaterials: Is the collateral damage inevitable?10.3389/fbioe.2019.00228 ↗
19. The effect of exposure to nanoparticles and nanomaterials on the mammalian epigenome10.2147/IJN.S120104 ↗
20. Self-functional gold nanoprobes for intra-nuclear epigenomic monitoring of cancer stem-like cells10.1016/j.bios.2021.113644 ↗
21. Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis10.3390/metabo11010028 ↗
22. Metabolic reprogramming in prostate cancer10.1038/s41416-021-01435-5 ↗
23. Isolation and Characterization of Potential Cancer Stem Cells from Solid Human Tumors—Potential Applications10.1002/0471141755.ph1428s63 ↗
24. Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarker10.1038/s41467-018-07214-w ↗
25. Reversible Control of Protein Corona Formation on Gold Nanoparticles Using Host–Guest Interactions10.1021/acsnano.9b08752 ↗
26. Predicting Metastasis from Cues of Metastatic Cancer Stem-like Cells-3D-Ultrasensitive Metasensor at a Single-Cell Level10.1021/acsnano.1c01436 ↗
27. Detection of gold nanoparticles with different sizes using absorption and fluorescence based method10.1016/j.snb.2015.12.044 ↗
28. Pilot · A Review on Surface-Enhanced Raman Scattering, Biosensors · 2019 · 9 · 57
29. Raman spectroscopy detects biochemical changes due to proliferation in mammalian cell cultures10.1529/biophysj.103.038604 ↗
30. Corona Composition Can Affect the Mechanisms Cells Use to Internalize Nanoparticles10.1021/acsnano.9b03824 ↗
31. Bai · In vivo Protein Corona Formation: Characterizations, Effects on Engineered Nanoparticles’ Biobehaviors, and Applications · 2021 · 9
32. SERS Probing of Proteins in Gold Nanoparticle Agglomerates10.3389/fchem.2019.00030 ↗
33. Protein Corona Influences Cellular Uptake of Gold Nanoparticles by Phagocytic and Nonphagocytic Cells in a Size-Dependent Manner10.1021/acsami.5b04290 ↗
34. Genome-Wide DNA Methylation Enhances Stemness in the Mechanical Selection of Tumor-Repopulating Cells10.3389/fbioe.2020.00088 ↗
35. Quantum scale organic semiconductors for SERS detection of DNA methylation and gene expression10.1038/s41467-020-14774-3 ↗
36. Quantum scale organic semiconductors for SERS detection of DNA methylation and gene expression10.1038/s41467-020-14774-3 ↗
37. SERS-Based Evaluation of the DNA Methylation Pattern Associated With Progression in Clonal Leukemogenesis of Down Syndrome10.3389/fbioe.2021.703268 ↗
38. Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
39. Oct4-Mediated Inhibition of Lsd1 Activity Promotes the Active and Primed State of Pluripotency Enhancers10.1016/j.celrep.2019.11.040 ↗
40. Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications
41. The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance10.1038/s41419-021-04116-6 ↗
42. Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies10.3389/fphar.2020.00904 ↗
43. The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links10.2174/1381612821666141211115611 ↗
44. Early detection and prediction of cancer metastasis – Unravelling metastasis initiating cell as a dynamic marker using self- functionalized nanosensors10.1016/j.snb.2022.131655 ↗
45. Impact of nanoparticle surface functionalization on the protein corona and cellular adhesion, uptake and transport10.1186/s12951-018-0394-6 ↗
46. Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy10.3389/fonc.2020.605386 ↗
47. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
48. Cancer signaling by plasmonic quantum probes
49. Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles10.1186/s11671-018-2728-6 ↗
50. Size, Shape, and Protein Corona Determine Cellular Uptake and Removal Mechanisms of Gold Nanoparticles10.1002/smll.201801451 ↗
51. Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies10.3389/fimmu.2020.01280 ↗
52. Cancer stem cell surface markers on normal stem cells10.5483/BMBRep.2017.50.6.039 ↗
53. The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance10.1038/s41419-021-04116-6 ↗
54. Molecular mechanisms governing the stem cell's fate in brain cancer: Factors of stemness and quiescence10.3389/fncel.2018.00388 ↗
55. Research progress on therapeutic targeting of quiescent cancer cells, Artificial Cells
56. The role of CD44 and cancer stem cells10.1007/978-1-4939-7401-6_3 ↗
57. The role of CD133 in cancer: a concise review10.1186/s40169-018-0198-1 ↗